Identification of Cuproptosis-Related Subtypes, Establishment of a Prognostic Signature and Characterization of the Tumor Microenvironment in Gastric Cancer
暂无分享,去创建一个
T. Fu | Jiazheng Li | Can Kong | Wei Song
[1] G. Zheng,et al. Cuproptosis-Mediated Patterns Characterized by Distinct Tumor Microenvironment and Predicted the Immunotherapy Response for Gastric Cancer , 2023, ACS omega.
[2] Mengna Zhang,et al. Comprehensive analysis of cuproptosis-related genes in prognosis, tumor microenvironment infiltration, and immunotherapy response in gastric cancer , 2022, Journal of Cancer Research and Clinical Oncology.
[3] S. Zhong,et al. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer , 2022, Frontiers in Immunology.
[4] Ronghua Yang,et al. Construction and Validation of a Novel Pyroptosis-Related Four-lncRNA Prognostic Signature Related to Gastric Cancer and Immune Infiltration , 2022, Frontiers in immunology.
[5] T. Golub,et al. Copper induces cell death by targeting lipoylated TCA cycle proteins , 2022, Science.
[6] Zhengrong Li,et al. A Necroptosis-Related lncRNA-Based Signature to Predict Prognosis and Probe Molecular Characteristics of Stomach Adenocarcinoma , 2022, Frontiers in Genetics.
[7] Junyu Huo,et al. A Five-Gene Signature Associated With DNA Damage Repair Molecular Subtype Predict Overall Survival for Hepatocellular Carcinoma , 2022, Frontiers in Genetics.
[8] Tong Liu,et al. A novel ferroptosis-related lncRNA signature for prognosis prediction in gastric cancer , 2021, BMC Cancer.
[9] Wei Song,et al. Identification of stem cell-related subtypes and risk scoring for gastric cancer based on stem genomic profiling , 2021, Stem cell research & therapy.
[10] Jun Ren,et al. Pyroptosis Patterns Characterized by Distinct Tumor Microenvironment Infiltration Landscapes in Gastric Cancer , 2021, Genes.
[11] X. Fang,et al. Construction on of a Ferroptosis-Related lncRNA-Based Model to Improve the Prognostic Evaluation of Gastric Cancer Patients Based on Bioinformatics , 2021, Frontiers in Genetics.
[12] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[13] V. Seshan,et al. The association between tumor mutational burden and prognosis is dependent on treatment context , 2020, Nature genetics.
[14] Ashton C. Berger,et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma , 2020, Nature Medicine.
[15] D. Vaux,et al. Cell Death in the Origin and Treatment of Cancer. , 2020, Molecular cell.
[16] J. Califano,et al. B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade , 2020, Clinical Cancer Research.
[17] Mengyu Sun,et al. Identification and validation of an individualized autophagy-clinical prognostic index in gastric cancer patients , 2020, Cancer Cell International.
[18] Jeffrey E. Lee,et al. B cells and tertiary lymphoid structures promote immunotherapy response , 2020, Nature.
[19] D. Cao,et al. High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients , 2019, Oncoimmunology.
[20] Peng Zhang,et al. Dissecting the Single-Cell Transcriptome Network Underlying Gastric Premalignant Lesions and Early Gastric Cancer. , 2019, Cell reports.
[21] R. DePinho,et al. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. , 2019, Cancer cell.
[22] C. Brennan,et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.
[23] N. Chaput,et al. Immunotherapy in advanced gastric cancer, is it the future? , 2019, Critical reviews in oncology/hematology.
[24] J. Utikal,et al. Circulating and Tumor Myeloid‐derived Suppressor Cells in Resectable Non‐Small Cell Lung Cancer , 2018, American journal of respiratory and critical care medicine.
[25] Xia Li,et al. TIP: A Web Server for Resolving Tumor Immunophenotype Profiling. , 2018, Cancer research.
[26] X. Liu,et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.
[27] Isabelle Salmon,et al. Methods of measurement for tumor mutational burden in tumor tissue. , 2018, Translational lung cancer research.
[28] R. Bourgon,et al. TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.
[29] F. Kühnel,et al. CD4 and CD8 T lymphocyte interplay in controlling tumor growth , 2017, Cellular and Molecular Life Sciences.
[30] C. Slingluff,et al. Vaccines targeting helper T cells for cancer immunotherapy. , 2017, Current opinion in immunology.
[31] J. Wargo,et al. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.
[32] Pornpimol Charoentong,et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade , 2016, bioRxiv.
[33] H. Stunnenberg,et al. Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells , 2016, Immunity.
[34] G. Gordon,et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. , 2016, The Lancet. Oncology.
[35] L. Zitvogel,et al. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] T. Kipps,et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. , 2016, The New England journal of medicine.
[37] Jason G. Jin,et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes , 2015, Nature Medicine.
[38] Steven J. M. Jones,et al. Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.
[39] G. Getz,et al. Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.
[40] Bin Tean Teh,et al. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. , 2013, Gastroenterology.
[41] Hao Xiong,et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[43] W. Wilson,et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. , 2010, The Lancet. Oncology.
[44] Stephen B Fox,et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] E. Elkin,et al. Decision Curve Analysis: A Novel Method for Evaluating Prediction Models , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.
[46] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[47] A. Wyllie,et al. Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.